73 results about "Cucurbitacin" patented technology

The present invention utilizes ultramicropulverization and dripping pill preparation production process to make cucurbitacin dripping pills, and can attain the goal of raising disintegration and dissolution speed, quickly obtaining therapeutic effect, raising stability of medicine, reducing dose of auxiliary material, reducing production cost and convenient administration. Said pill not only can be sucked, but also can be swallowed.

Method and pharmaceutical composition for treating anemia related symptoms. The method and formulation involve the use of one or more cucurbitacin analogs as active ingredients, for example, cucurbitacin D, which are capable of increasing hemoglobin expression, reactivating fetal or adult hemoglobin and inducing γ-globin.

The invention relates to a natural botanical vermin-proof agent, which is prepared from medicinal plants materials including datura flower, roor of sessile stemona, galangal rhizome, cucurbitacin, asaryl, clove, chestnut bark, aromatic plants, camphor, mentha and boneol.

The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a cucurbitacin using the signaling molecules in the Ras-Raf-Mek-Elk-STAT3 pathway.

Baits useful against diabroticine mature and immature beetles contain (a) an insecticide and (b) a feeding stimulant containing a cucurbitacin in a gelatin binder.

The invention discloses a new medicament application of cucurbitacins, namely an application of mixing effective monomers of cucurbitacins in medicament for treating leukaemia or an application of effective monomers of cucurbitacins to independently treating leukaemia, belonging to the technical field of medicament. The cucurbitacins with nano-mole concentration can obviously inhibit multiplication of leukaemia HL60 and K562 cells; the cucurbitacins have no cell toxic effect to human leukaemia cells in a multiplication inhibiting concentration range; and the multiplication inhibiting effect to leukaemia cells in vitro is stronger than that to solid tumour cells. Further researches suggest that the cucurbitacins with micro-mole concentration can induce apoptosis of leukaemia HL60 cells by increasing cucurbitacin concentration. Anti-tumour researches in vivo suggest that the cucurbitacins can prolong survival time of a small mouse P388 leukaemia animal model. The effective monomers of cucurbitacins in resisting leukaemia have obvious effect, low toxicity, long lasting drug administration, can be used for both chemotherapy and radiotherapy, and are promising to be further developed into the medicament for treating leukaemia.

The invention discloses a method for extracting and separating cucurbitacin B, which comprises the following steps: firstly, melon pedicels as a raw material are crushed and are refluxed and extracted by ethanol diacolation or ethanol, an extracting solution is extracted by ethyl acetate more than three times after being concentrated, and the ethyl acetate is recovered to obtain a total cucurbitacin extract; secondly, the total cucurbitacin extract is taken to be dissolved in a 25 to 45 percent of ethanol water solution, and the hydrolysis reaction is carried out in the presence of acetic acid; the pH value is adjusted to be neutral after full reaction, and the extract is concentrated to dry; and then the obtained extract is treated by purification so as to obtain a cucurbitacin B product with more than 60 percent of cucurbitacin B content, and the concentration of the acetic acid is 0.1 to 0.3 mol / L. Compared with the prior art for extracting and separating cucurbitacin B, the invention has the following advantages: the analogue (such as cucurbitacin B glucoside) of the cucurbitacin B is converted into the cucurbitacin B by the structural transformation in the process of extraction, so that the extraction rate of the cucurbitacin B is improved, the production process is simple, and the operation is simple.

The invention relates to a cucurbitacin soft capsule oral medicament and process for preparation, wherein the medicament includes medicinal soup and capsule shell, wherein each tablet of the soup comprises micronized cucurbitacin 0.01-10mg, dissolvent and stabilizing agent, the shell contains gelatin, plasticizing agent, preservative agent, screening agent, flavoring agent and coloring matter.

The invention discloses a new application of cucurbitacins and drug composition to treat pancreatic cancer in the medical technical domain, which is characterized by the following: adopting cucurbitacins and drug composition as raw material to prepare multiple kinds of agent, such as tablet, powder medicine, capsule, particle, turbid liquor, syrup, oral liquor, chrisma, paster and injection; fitting for giving drug individually or integrally to treat low leucocyte of pancreatic cancer and tumour patient due to radiotherapy; setting the drug supplying content at 0. 001mg / kg-1mg / kg for mouse, 0. 1mg-5mg / d for health people with optimum content at 0. 01mg / kg-0. 5mg / kg for mouse, 0. 3mg-3mg / d for health people every 1-4 times one day.

The invention provides a preparation method of a cucurbitacin type compound. The preparation method comprises the steps of extracting pedicellus melo by using an organic solvent, performing solvent distribution on an extract, and performing silica gel column separation and purification by high performance liquid chromatography on a sample after concentration to obtain a cucurbitacin mixture and a cucurbitaceae type compound. Through an anti-aging yeast model-K6001 yeast cell, an active ingredient, namely the cucurbitacin type compound is proved to be capable of significantly prolonging the replicative life span of yeast, so that the cucurbitacin mixture and the cucurbitaceae type compound can be applied in preparation of medicaments for preventing and treating aging and preventing or / and treating age-related diseases. Simultaneously, the cucurbitacin mixture and the cucurbitaceae type compound can also be applied in preparation of nutritional compositions for delaying aging and preventing age-related diseases. The compound can also be used as a lead compound for optimizing the structure and can be applied in preparation of medicaments for delaying aging and preventing or / and treating age-related diseases. The general formula of the structure of the compound is shown in the specification.

The invention belongs to the technical field of medicine and discloses novel application of Cucurbitacins, namely novel application of Cucurbitacin B, Cucurbitacin B substances, Cucurbitacin BE and a pharmaceutical composition thereof in a medicine for treating ovarian cancer and improving the quantity of leukocytes of radiotherapy patients. The Cucurbitacin can also be a cucurbitacin B monomer, an isocucurbitacin B monomer, a dihydrocucurbitacin B monomer, a cucurbitacin I monomer, and a cucurbitacin O monomer. The Cucurbitacins or pharmaceutical compositions thereof can be matched with a pharmaceutically acceptable carrier and prepared into a tablet, a capsule, a granule, powder, a plaster, an ointment, an aerosol, a suspension, a syrup, an oral liquid, and an injection, and can also beprepared into special dosage forms such as a liposome, microspheres, nanoparticles and an emulsion for cavity administration, external use, oral administration and injection. The individual administration or the combined treatment can be performed, the administration dosage of the Cucurbitacins is calculated according to the total Cucurbitacins, the dosage for healthy adults is between 0.1 and 5mg / d, the best dosage is between 0.3 and 3mg / d, and the administration is performed for 1 to 4 times.

The invention discloses a new usage of cucurbitacin (Cucurbitacins) in medicinal technique domain, which is characterized by the following: using cucurbitacin and medicinal component to treat laryngocarcinoma and increase quantity of leukocyte; preparing to multiple agent type such as tablet, powder medicine, capsule, granula, oral liquid, injection and so on with the cucurbitacin or medicinal component; proceeding independent give drug or combined treatment; using to leucopenia because of radiotheraphy of tumor patient; counting the give drug dosage of cucurbitacin with total cucurbitacin; giving the drug to mouse with 0. 001mg / kg-1mg / kg; giving to adult with 0. 1mg-5mg / day.

The invention discloses a cucurbitacin nanometer agent with protein, which can be liquid agent or solid agent. The protein nanometer particle can be reserved under indoor temperature, which improves drug quality and effect. the liquid agent contains0.05-10% (W / V) protein quantity and 0.001-1% (W / V) cucurbitacin and the solid agent consists of 50-99.9% (W / V) protein and 0.001-50% (W / V) cucurbitacin.

The invention provides a preparation method of cucurbitacin compounds, which comprises the following steps: pulverizing and leaching traditional Chinese medicine muskmelon pedicel, carrying out solvent partitioning on the crude leaching sample with a methanol water solution and n-hexane, concentrating, respectively separating the concentrate with a normal-phase silica gel chromatographic column, and purifying by high performance liquid chromatography to obtain the purified cucurbitacin compounds. The cucurbitacin compounds obtained in the invention have obvious quasi-nerve growth factor activity, and can be applied to preparation of medicines for preventing senile dementia and other neurodegenerative diseases and especially to preparation of medicines for treating Alzheimer's disease and other neurodegenerative diseases. The invention develops pharmaceutical application of effective component cucurbitacin compounds. The raw material-traditional Chinese medicine muskmelon pedicel has wide sources and is convenient to take; and the preparation method is simple and can easily implement industrial production. The structural general formula is disclosed in the specification.

The invention aims at providing a cucurbitacin solid lipid nanoparticle preparation and a preparation method thereof, which can effectively solve the problems of poor stability and low quality in the prior art. The technical scheme provided by the invention is that: in the preparation, the weight ratio of cucurbitacin, lipid material and surface active agent is 0.001-30:0.01-99:0.01-50, and the sum of the cucurbitacin, the lipid material and the surface active agent accounts for 0.1-40% of the total weight of the raw materials of the nanoparticle preparation. The preparation method is as follows: heating and melting the lipid material, the surface active agent and the cucurbitacin in dark place, fully and evenly stirring; adding water for dispersing to nanoscale; filtering and cooling in the melting state. The invention has scientific and simple composition, scientific compatibility, reasonable dosage, convenient use and fine stability. The invention integrates the advantages of high physical stability and low drug leakage of polymer nanoparticles with low toxicity and capability of large-scale production of liposome and emulsion, which is an innovation in cucurbitacin solid lipid nanoparticle preparation and has enormous economical and social benefits.

A dripping pill of cucurbitacin for treating chronic metastatic hepatitis features high natural level and safety and low toxic by-effect. Its preparing process is also disclosed.

The invention relates to a transdermal administration composite containing cucurbitacin-type active ingredient. The transdermal transparent accelerator in the transdermal administration preparation of the cucurbitacin-type active ingredient is one or more composites of oleic acid, azone, eucalyptus oil, or isopropyl myristate and the like, and the dosage of the transdermal transparent accelerator is 0.1 to 50%, and 0.3 to 30% is preferred. The transdermal administration of cucurbitacin-type active ingredient can adopt liquid or semisolid preparation of gels, emulsion, ointment, solution agent, micro-emulsion, ethosomes or nebula and the like, or emplastrum such as patch, cataplasma and the like. After the transdermal administration of the preparations, the active ingredient can be absorbed by skin continuously and enter into human body to play a therapeutic role for a long while, the patient adaptability is significantly better than oral administration medication, therefore, the transdermal administration composite can be used for preventing and curing of hepatitis, cancer and other diseases and improving quality life of patients.

The invention provides a total cucurbitacin phosphatidyl cholate mixed micelle oral quick-absorption membrane and a preparation method thereof, and belongs to the technical field of traditional Chinese medicinal preparations and preparation methods thereof. The preparation method comprises the following steps: preparing a lipid membrane from phospholipid; dissolving cholate into a phosphate buffer solution to prepare a cholate liquid; performing ultrasonic mixing on the lipid membrane and the cholate liquid in a water bath to obtain a phosphatidyl cholate blank micelle liquid; adding total cucurbitacin powder into the phosphatidyl cholate blank micelle liquid to obtain phosphatidyl cholate mixed micelle of total cucurbitacin; sequentially adding hydroxypropyl methyl cellulose, low substituted hydroxyprepyl cellulose, microcrystalline cellulose and PEG400 (polyethylene glycol 400) into the phosphatidyl cholate mixed micelle of total cucurbitacin to obtain the total cucurbitacin phosphatidyl cholate mixed micelle oral quick-absorption membrane. The oral quick-absorption membrane has the advantages of improving the solubility of total cucurbitacin, increasing adhesive and penetrating effect of the oral quick-absorption membrane to oral mucosa, avoiding irritation of total cucurbitacin to gastrointestinal tracts, remarkably improving the bioavailability of total cucurbitacin and reducing adverse response.

A pure cucurbitacin product is obtained through conducting grinding, petroleum ether leaching and filtering on siraitia grosvenorii roots, adsorbing by resin after reduced pressure concentration on filtrate, eluting by different concentrations of eluents, decoloring the eluents, crystallizing and recrystallizing, and starch is obtained by jordaning filter residue, filtering to obtain starch milk, precipitating the starch milk through centrifugal separation, and drying or dehydrating 95% of ethanol. The cucurbitacin substances and the starch substances can be obtained at the same time by the method, so that the utilization rate of the siraitia grosvenorii roots is improved greatly, the starch resource is saved, the operation is simple, the residual of cucurbitacins in the starch in siraitia grosvenorii roots is reduced greatly, and the use scope of starch is expanded.

The invention provides a cucurbitacin medicinal composition and pharmaceutical application thereof. The cucurbitacin medicinal composition comprises cucurbitacin, a solubilizer, an antioxidant and a pH regulator, wherein the using amount of the pH regulator is enough for regulating the pH value of the medicinal composition to 3.5-7.5; the weight ratio of the cucurbitacin to the solubilizer is (1:600)-(1:3,150). The medicinal composition can be used for preparing medicaments for lowering the toxicity of cucurbitacin as well as anti-hepatitis, jaundice-removing and anti-cancer medicaments.

The invention discloses a nutritional pet feed which comprises the following raw materials by mass: 4-7 parts of animal proteins, 12-16 parts of plant proteins, 12-15 parts of plant fibers, 1-2 parts of salt, 4-6 parts of animal fat, 10-15 parts of corn starch, 25-30 parts of wheat flour, 1-2 parts of shrimp shell meal, 15-25 parts of wheat gluten, 40-45 parts of potato powder, 25-30 parts of gelatin, 3-4 parts of lycopene, 12-15 parts of glycerol, 3-4 parts of edible oil, 1-5 parts of threonine, 5-10 parts of egg white powder, 1-2 parts of dried orange peel powder, 2-3 parts of lysine, 10-30 parts of flour, 8-9 parts of lysine, 20-30 parts of corn flour, 10-30 parts of bean cakes, 3-5 parts of dried shrimps, 5-10 parts of bone powder, 15-20 parts of potato powder, 2-3 parts of yeasts, 2-3 parts of vitamin and 1-2 parts of cucurbitacin. The nutritional pet feed provided by the invention is rich in nutrition and easy to digest.

The present invention belongs to the field of medicine technology, and provides cucurbitacin refining process and preparation. The cucurbitacin refining process includes the following steps: 1. dissolving marketed cucurbitacin in C1-C4 alcohol-water dissolved ketone to obtain solution A containing cucurbitacin in 0.1-10 g each 100ml; 2. adding active carbon in0.01-10 g for each 100 ml, stirring for 1-60 min and filtering out carbon to obtain solution B; 3. adding water into solution B to reach alcohol / water volume ratio of 1 to 1-10, and stirring until the solution becomes turbid; 4. letting stand for over night; and 5. filtering, collecting precipitate and drying. The refining process can lower the toxicity of cucurbitacin product, has no altering on cucurbitacin B content and is suitable for industrial production. The cucurbitacin product may be prepared into different preparations for treating tumors, increasing peripheral blood leukocytes and treating hepatitis.

The invention discloses a cucurbitacin nanometer agent with protein, which can be liquid agent or solid agent. The protein nanometer particle can be reserved under indoor temperature, which improves drug quality and effect. the liquid agent contains0.05-10% (W / V) protein quantity and 0.001-1% (W / V) cucurbitacin and the solid agent consists of 50-99.9% (W / V) protein and 0.001-50% (W / V) cucurbitacin.

The invention provides a HPLC method for simultaneously determining content of cucurbitacin and dihydrocucurbitacin F in hemsleya amabilis. The method comprises the following steps of: a, preparing atest solution; b, preparing a reference solution; c, respectively injecting the test solution and the reference solution into a high performance liquid chromatography for detection; and d, calculatingthe content of the cucurbitacin and the dihydrocucurbitacin F in the hemsleya amabilis according to the detection result. The HPLC method can simultaneously detect the content of the su-hemsleya in the hemsleya amabilis, can be used for identifying different base source varieties of the hemsleya amabilis, and lays a foundation for improving the quality control level of the hemsleya amabilis and promoting development and utilization of medicinal materials.

The invention belongs to the technical field of medicines, and discloses application of cucurbitacin in the preparation of medicaments for treating cough. The cucurbitacin comprises cucurbitacin A, B, C, D, E, I, Q and S, dihydrocucurbitacin A, B, C, D, E, I, Q and S, isocucurbitacin A, B, C, D, E, I, Q and S, and one or more than two of glucoside substances corresponding to each cucurbitacin. The cucurbitacin can be prepared into tablets, capsules, granules, powder, suspensions, syrups, oral liquid, patch, ointment, aerosol, suppository, nose drops or injection and the like with a pharmaceutically-acceptable carrier, can be used for treating the cough caused by various reasons, and has the effect of eliminating phlegm. The dose of healthy adults is between 0.1 and 5 mg / d, and preferable is between 0.3 and 3 mg / d; and the dose of children is subjected to discretionary reduction.

The invention relates to a slow-release preparation of cucurbitacin, a natural antibiotic. The slow-release preparation is in the special dosage form and is a membrane controlled-release or / and skeleton-release oral preparation formed by the following components in percentage by weight: 5-20% of cucurbitacin, 30-65% of water insoluble polymers for medicine, 5-25% of water soluble polymers for medicine and 15-45% of conventional adjuvants. The preparation can slow down release of cucurbitacin from the medicinal preparation, thus reducing peak valley of medicine absorption and being beneficial to maintaining steady plasma concentration. In particular, when the medicine release mode combining quick release and slow release is adopted, the quick-release part of cucurbitacin is quickly released after oral administration, thus being beneficial to building the plasma concentration meeting treatment requirement, while the slow-release part of cucurbitacin can provide comparatively steady plasma concentration in the following period, thus reducing fluctuation of plasma concentration and being more beneficial to disease treatment.

The invention discloses a treatment agent of domestic sewage, prepared from the following raw materials in parts by weight: 5-15 parts of attapulgite, 4-12 parts of ferric chloride, 24-38 parts of coal gangue, 14-24 parts of montmorillonite, 6-10 parts of polyacrylamide, 10-16 parts of straw, 8-15 parts of starch, 2-5 parts of activated carbon, 18-30 parts of modified diatomite and 0.5-4 parts of cucurbitacin. The invention also discloses a preparation method of the chemical. The treatment agent of domestic sewage has broad sources of raw materials, low cost of raw materials, a simple preparation process, low equipment investment cost and applicability to large-scale industrial production; the cucurbitacin, straw, coal gangue, modified diatomite and other components in the treatment agent play a synergetic effect; and the treatment agent has low dosage, good treatment effect, stable performance and good quality of effluent water, reduces the cost of water treatment and has good economic benefit and social benefit.

The invention relates to a pharmaceutical composition for treating liver cancer, which is prepared by proportionally mixing crude drugs including peimine, oroxin A, cucurbitacin and justicidin A. The pharmaceutical composition can be prepared in various forms according to conventional preparation technologies. The pharmaceutical composition provided by the invention is of great significance in preparation of drugs for treating liver cancer.

The invention relates to a pharmaceutical composition for treating AIDS. The pharmaceutical composition is prepared from raw materials of amentoflavone, cucurbitacin, peimine and protostemonine in certain proportion; and the pharmaceutical composition can be prepared into various dosage forms according to the conventional preparation process. The pharmaceutical composition provided by the invention has great significance to the preparation of medicaments for the treatment of AIDS.